NRX Archives - Page 4 of 6 - NRx Pharmaceuticals

Jun. 22, 2022

Class Action Suit Against NRx Pharmaceuticals Dismissed

NRx Pharmaceuticals, Inc. is pleased to announce that on June 13, 2022, the plaintiffs in the securities class action lawsuit captioned “Dal Bosco v. NRx Pharmaceuticals, Inc. et al.” filed a notice in the U.S. District Court for the District of Delaware voluntarily dismissing the action against NRx Pharmaceuticals and its former officers. The dismissal was made without prejudice.

Jun. 7, 2022

NRx Pharmaceuticals Appoints Seth Van Voorhees, PhD, as Chief Financial Officer and Treasurer

NRx Pharmaceuticals, Inc. announced today that the company’s Board of Directors appointed Seth Van Voorhees, Ph.D. as Chief Financial Officer and Treasurer effective June 13, 2022.

May. 25, 2022

NRx Pharmaceuticals Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI® (aviptadil) in Critical COVID-19

NRx Pharmaceuticals, Inc. today announced results of a review conducted by the Data Safety and Monitoring Board (DSMB) on May 25, 2022. The DSMB reviewed data of approximately 460 patients with Critical COVID-19 Respiratory Failure who were enrolled in the ACTIV-3b (TESICO) trial, most of which had reached the 90-day endpoint.

May. 16, 2022

NRx Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, NRx Pharmaceuticals), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter ended March 31, 2022 and provided a business and clinical update.

May. 12, 2022

NRx Pharmaceuticals Announces Enrollment of First Patient in Phase II Study of Bipolar Depression with Sub-Acute Suicidality

NRx Pharmaceuticals enrolled its first patient in one of two psychiatry studies being initiated this year; this first trial is studying patients with bipolar depression and sub-acute suicidality.

May. 10, 2022

NRx Pharmaceuticals to Report First Quarter 2022 Results on May 16, 2022

NRx Pharmaceuticals, Inc. today announced that management will report first quarter 2022 financial results prior to the market open on May 16, 2022.

Apr. 8, 2022

NRx Pharmaceuticals’ Interim CEO Presentation at 21st Annual Needham Virtual Healthcare Conference

The 21st Annual Needham Virtual Healthcare Conference took place on April 11-14, 2022 and featured fireside chats and presentations from leading public and private companies in the Biotechnology, Specialty Pharmaceuticals, Medical Technology, and Diagnostics sectors. Watch as NRx CEO Robert Besthof, M.I.M. gave a corporate presentation.

Mar. 31, 2022

NRx Pharmaceuticals Provides Business Update and Reports Full Year 2021 Financial Results

NRx Pharmaceuticals, Inc. today announced its financial results for the year ended December 31, 2021 and provided a business update.

Mar. 31, 2022

I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Suggests No Clinical Benefit with Addition of Nebulized ZYESAMI® (aviptadil) when given by mouth inhalation in Critically Ill Patients with COVID-19

Quantum Leap Healthcare Collaborative (QLHC) announced in collaboration with NRx Pharmaceuticals, Inc. (NRx), that the nebulized form of ZYESAMI® (Aviptadil), in the I-SPY COVID Trial of Critical COVID-19 patients has been stopped.

Cookie	Duration	Description
_wpfuuid	11 years	This cookie is used by the WPForms WordPress plugin. The cookie is used to allows the paid version of the plugin to connect entries by the same user and is used for some additional features like the Form Abandonment addon.
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
nlbi_1816097	session	A load balancing cookie set to ensure requests by a client are sent to the same origin server.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
visid_incap_1816097	1 year	SiteLock sets this cookie to provide cloud-based website security services.

Cookie	Duration	Description
_jsuid	1 year	This cookie contains random number which is generated when a visitor visits the website for the first time. This cookie is used to identify the new visitors to the website.
cluid	1 year	This cookie is used for websites which is having multiple domains to identify the same visitor across multiple domains.
CONSENT	2 years	YouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
mo_has_visited	11 years	This cookie is used for setting an unique ID for the visitor which helps to get the accurate number of specific visitor on the website.
mo_is_new	session	This cookie is used for counting the new visitors to the website by assigning a unique visitor ID.
mo_page_views_counter	session	This cookie is used for counting the new visitors to the website by assigning a unique visitor ID.

Cookie	Duration	Description
c	6 months 2 days	This cookie is set by Rubicon Project to control synchronization of user identification and exchange of user data between various ad services.
uuid	1 year 27 days	MediaMath sets this cookie to avoid the same ads from being shown repeatedly and for relevant advertising.
VISITOR_INFO1_LIVE	5 months 27 days	A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
YSC	session	YSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages.
yt-remote-connected-devices	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt-remote-device-id	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.

Cookie	Duration	Description
incap_ses_1371_1816097	session	No description
unpoco_101344884	1 day	No description